Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CTSB | P07858 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CTSS | P25774 | 1/20 | 0.67 |
| ▸ | CTSK | P43235 | 1/20 | 0.67 |
| ▸ | GRN | P28799 | 4/20 | 0.65 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158900 | 1.00 | CTSL (0.67) | CTSLCA2CTSBCA1CTSS | |
| SCHEMBL2158906 | 1.00 | CTSL (0.67) | CTSLCA2CTSBCA1CTSS | |
| SCHEMBL20277660 | 0.88 | CTSL (0.65) | CTSLCA2CTSBCA1CTSS | |
| SCHEMBL1640054 | 0.88 | NAALAD2 (0.58) | CTSLCA2CTSBCA1CTSS | |
| SCHEMBL9830474 | 0.87 | PSMB5 (0.72) | CTSLCTSBCTSSCTSKMME | |
| SCHEMBL9830466 | 0.87 | PSMB5 (0.72) | CTSLCTSBCTSSCTSKMME | |
| SCHEMBL4160513 | 0.87 | CA2 (0.68) | CTSLCA2CTSBCA1CTSS | |
| SCHEMBL31611853 | 0.87 | CA2 (0.68) | CTSLCA2CTSBCA1CTSS | |
| SCHEMBL17822178 | 0.87 | HPGDS (0.65) | CTSLCA2CTSBCA1CTSS | |
| SCHEMBL7432512 | 0.87 | CTSL (0.63) | CTSLCA2CTSBCA1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1634892-A | Method for resolution of isoquinolines | XUZHOU NHWA PHARM GROUP CO LTD (CN) | 2005-07-06 | — | — | CN | claimed |
| EP-3466961-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Li, Min (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9434760-B2 | Prolinamide derivatives as thrombin inhibitors, preparation method and application thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-09-06 | — | — | US | disclosed |
| EP-2824097-A1 | Prolinamide derivative as thrombin inhibitor, preparation method and application thereof | Shanghai Institute of Pharmaceutical Industry (CN) | 2015-01-14 | — | — | EP | disclosed |
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-11-07 | — | — | US | disclosed |
| EP-2639230-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-09-18 | — | — | EP | disclosed |
| CN-102464701-A | Novel compound, preparation method and application thereof | SHANGHAI INST PHARM INDUSTRY | 2012-05-23 | — | — | CN | disclosed |
| US-20090042260-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE (S OR R)-ALPHA-AMINO ACID AND OPTICALLY ACTIVE (R OR S)-ALPHA-AMINO ACID ESTER | UBE INDUSTRIES, LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1942193-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE (S OR R)-a-AMINO ACID OR OPTICALLY ACTIVE (S OR R)-a -AMINO ACID ESTER | Ube Industries, Ltd. (JP) | 2008-07-09 | — | — | EP | disclosed |
| CN-1634892-A | Method for resolution of isoquinolines | XUZHOU NHWA PHARM GROUP CO LTD (CN) | 2005-07-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | PREP, TFPI, PEPD | CTSL 66/4885CA2 3135/4885CTSB 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.